Thursday, July 3, 2025 7/3/2025

BIVALENT RECOMBINANT LHN BOTULINUM VACCINE (SEROTYPES A AND B)

Award Number: U01AI077910
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/25/2008
PERIOD OF PERFORMANCE END DATE: 05/31/2011

Group Awards By:

View Award Description

BIVALENT RECOMBINANT LHN BOTULINUM VACCINE (SEROTYPES A AND B) - DESCRIPTION (provided by applicant): Botulinum neurotoxins are a family of seven (serotypes A-G) pharmacologically similar but serologically distinct potent neuroparalytic proteins produced by strains of Clostridium botulinum. They are recognized as the most poisonous toxins known and are designated by CDC as Category A biothreat agents. Vaccines provide the only comprehensive means of protection against botulinum intoxication. However, there are currently no FDA-approved botulinum vaccines, and the existing pentavalent botulinum toxoid (PBT) vaccine (an IND product for the last 35 years) was last formulated in 1990s from components manufactured in the early 1970s. The supply of PBT is extremely limited, and the product appears to be decreasing in potency. There are other recombinant botulinum vaccines under development, and they are mostly based on the heavy chain (Hc) fragment of the toxin molecule. Intrinsic properties of the Hc fragment present challenges to the use of Hc as a vaccine candidate: issues associated with vaccine formulation, stability and protection against engineered toxins. To address the urgent unmet medical need for an effective botulinum vaccine, Emergent Product Development Gaithersburg (Emergent) has internally funded the development of a recombinant botulinum vaccine (rBot) based on the LHN fragment of the toxin molecule. The LHN-based vaccine candidate offers advantages over other recombinant approaches, including improved stability, cross- protection against toxin subtypes and ease of formulation into a multivalent vaccine. The overall objective of the proposed work is to develop a safe and efficacious vaccine against botulinum neurotoxin serotypes A and B, which are viewed as the most prominent biothreat serotypes. Additional serotypes can be added to the vaccine formulation later if the U.S. Government so desires. Immunogenicity and efficacy testing in guinea pigs and mice has shown that this approach produces a strong and protective immune response and is effective against toxin subtypes. To undertake this research program, Emergent has partnered with the Health Protection Agency (Porton Down, UK). Together, these organizations offer a wealth of experience in botulinum vaccine development. Advanced process development has been completed, and a consistent and commercially viable manufacturing process has been developed that produces highly purified and soluble LHN proteins. The specific aims of this grant include activities required for entrance into Phase 1 clinical trial: 1. Pre-clinical Testing of Monovalent LHN/A&B and Bivalent LHN/AB Vaccine 2. Manufacture of cGMP Clinical Lots (Monovalent LHN/A, B and Bivalent LHN/AB Final Product) 3. Stability Testing of cGMP Clinical Lots (LHN/A, B and LHN/AB)


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2010 ( Subtotal = $399,412 )
2010	2010	EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP	300 PROFESSIONAL DRIVE	GAITHERSBURG	MD	20879	MONTGOMERY	USA	Allergy and Infectious Diseases Research	001	3	6/9/2010	NON-COMPETING CONTINUATION	$399,412
2010	2010	EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP	300 PROFESSIONAL DRIVE	GAITHERSBURG	MD	20879	MONTGOMERY	USA	Allergy and Infectious Diseases Research	002	3	9/23/2010	NON-COMPETING CONTINUATION	$0
2010	2009	EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP	300 PROFESSIONAL DRIVE	GAITHERSBURG	MD	20879	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2	11/20/2009	NON-COMPETING CONTINUATION	$0
														Subtotal = $399,412

Issue Date FY: 2009 ( Subtotal = $694,454 )
2009	2009	EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP	300 PROFESSIONAL DRIVE	GAITHERSBURG	MD	20879	MONTGOMERY	USA	Allergy and Infectious Diseases Research	001	2	7/17/2009	NON-COMPETING CONTINUATION	$694,454
2009	2008	EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP	300 PROFESSIONAL DRIVE	GAITHERSBURG	MD	20879	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	1	1/30/2009	NEW	$0
														Subtotal = $694,454

Issue Date FY: 2008 ( Subtotal = $711,872 )
2008	2008	EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP	300 PROFESSIONAL DRIVE	GAITHERSBURG	MD	20879	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	1	6/25/2008	NEW	$711,872
														Subtotal = $711,872

Grand Total All Awards = $1,805,738

Top

All Categories

About

Search

Reports

Data Submission

Award Information

BIVALENT RECOMBINANT LHN BOTULINUM VACCINE (SEROTYPES A AND B)

Award Number: U01AI077910

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/25/2008

PERIOD OF PERFORMANCE END DATE: 05/31/2011

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer